Vnitr Lek 2023, 69(8):E10-E18 | DOI: 10.36290/vnl.2023.107

Sepsis - associated disseminated intravascular coagulation - a constant problem of the present

Jaromír Tupý
Klinika hematológie a transfuziológie, ÚVN SNP Ružomberok - FN
Fakulta zdravotníctva, Katolícka univerzita v Ružomberku

Disseminated intravascular coagulation (DIC) is a common and life-threatening complication in sepsis. Sepsis-associated DIC is recognized as the systemic activation in coagulation with suppressed fibrinolysis that leads to organ dysfunction in combination with systemic intravascular inflammation. In this proces, thrombin, neutrophils, platelets, endothelium and damage-associated molecular patterns play a key role as part of immunothrombosis. Recent advances in the understanding of pathophysiology have made it possible to diagnose sepsis-associated DIC at earlier timing and with better accuracy. However, progress in the treatment is still limited, and requires new therapeutics for sepsis-associated DIC.

Keywords: sepsis, disseminated intravascular coagulation, immunothrombosis, sepsis-induced coagulation

Accepted: December 5, 2023; Published: December 18, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tupý J. Sepsis - associated disseminated intravascular coagulation - a constant problem of the present. Vnitr Lek. 2023;69(8):E10-18. doi: 10.36290/vnl.2023.107.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-810. Go to original source... Go to PubMed...
    2. The Brussels Sepsis Resolution. Global Sepsis Alliance, Brussels, March 20th, 2018.
    3. Howell MD, Davis AM. Management of sepsis and septic shock. JAMA.2017;317:847-8. Go to original source... Go to PubMed...
    4. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(01):34-45. Go to original source... Go to PubMed...
    5. Martinod K, Deppermann C. Immunothrombosis and thromboinflammation in host defense and disease. Platelets. 2021;32(3):314-324. Go to original source... Go to PubMed...
    6. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30. Go to original source...
    7. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7:e017046. Go to original source... Go to PubMed...
    8. Iba T, Helms J, Connors JM, Levy JH. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2023; 11(1):24. Go to original source... Go to PubMed...
    9. Gando S, Fujishima S, Saitoh D, Shiraishi A, et al. The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome. Thromb Res. 2020;191:15-21. Go to original source... Go to PubMed...
    10. Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis‑associated DIC. International Journal of Hematology. 2021;113:24-33. Go to original source... Go to PubMed...
    11. Futosi K, Fodor S, Mócsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int Immunopharmacol. 2013;17(3):638-50. Go to original source... Go to PubMed...
    12. Iba T, Levi M, Levy JH. Intracellular communication and immunothrombosis in sepsis. J Thromb Haemost. 2022;20(11):2475-84. Go to original source... Go to PubMed...
    13. Salomão R, Martins PS, Brunialti MK, et al. TLR signaling pathway in patients with sepsis. Shock. 2008;30(Suppl 1):73-7. Go to original source... Go to PubMed...
    14. Liaw PC, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2016;30(04):257-261. Go to original source... Go to PubMed...
    15. Gould TJ, Lysov Z, Swystun LL, et al. Canadian Critical Care Translational Biology Group. Extracellular histones increase tissue factor activity and enhance thrombin generation by human blood monocytes. Shock. 2016;46(6):655-62. Go to original source... Go to PubMed...
    16. Pérez-Figueroa E, Álvarez-Carrasco P, Ortega E, Maldonado-Bernal C. Neutrophils: many ways to die. Front Immunol. 2021;12:631821. Go to original source... Go to PubMed...
    17. Bonaventura A, Liberale L, Carbone F, et al. The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases. Thromb Haemost. 2018;118(1):6-27. Go to original source... Go to PubMed...
    18. Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020; 130(11):6151-6157. Go to original source... Go to PubMed...
    19. Assinger A, Schrottmaier WC, Salzmann M, Rayes J. Platelets in sepsis: an update on experimental models and clinical data. Front Immunol. 2019;10:1687. Go to original source... Go to PubMed...
    20. José RJ, Williams AE, Mercer PF, Sulikowski MG, Brown JS, Chambers RC. Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. J Immunol. 2015;194(12):6024-34. Go to original source... Go to PubMed...
    21. Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. Am J Respir Crit Care Med. 2020;202(3):361-70. Go to original source... Go to PubMed...
    22. Ito T, Kakuuchi M, Maruyama I. Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. Crit Care. 2021;25(1):95. Go to original source... Go to PubMed...
    23. Jamal M, Bangash HI, Habiba M et al. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918-936. Go to original source... Go to PubMed...
    24. Bitker L, Burrell LM. Classic and nonclassic renin-angiotensin systems in the critically ill. Crit Care Clin. 2019;35(2):213-27. Go to original source... Go to PubMed...
    25. Higgins SJ, De Ceunynck K, Kellum JA, et al. Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest. 2018;128(4):1471-84. Go to original source... Go to PubMed...
    26. Novotný J, Penka M. Poruchy hemostázy u sepse. Vnitř Lék. 2012;58(6):439-447.
    27. Taylor FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30. Go to original source...
    28. Gando S, Iba T, Eguchi Y, Ohtomo Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-31. Go to original source... Go to PubMed...
    29. Singh RK, Baronia AK, Sahoo JN, et al. Prospective comparison of new Japanese Association for Acute Medicine (JAAM) DIC and International Society of Thrombosis and Hemostasis (ISTH) DIC score in critically ill septic patients. Thromb Res. 2012;129:e119-25. Go to original source... Go to PubMed...
    30. Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019;9:19. Go to original source... Go to PubMed...
    31. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, et al. A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. Clin Appl Thromb Hemost. 2018;24:439-45. Go to original source... Go to PubMed...
    32. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17:1989-1994. Go to original source... Go to PubMed...
    33. Iba T, Levy JH, Yamakawa K, et al. Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. J Thromb Haemost. 2019;17:1265-68. Go to original source... Go to PubMed...
    34. Zou ZY, Huang JJ, Luan YY, et al. Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database. Burns Trauma. 2022;10:029. Go to original source... Go to PubMed...
    35. Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2020;46:89-95. Go to original source... Go to PubMed...
    36. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360 Go to original source... Go to PubMed...
    37. Iba T. et al.. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. Journal of Intensive Care. 2019;4:32. Go to original source... Go to PubMed...
    38. Yamakawa K, Yoshimura J, Ito T, et al. External validation of the two newly proposed criteria for assessing coagulopathy in sepsis. Thromb Haemost. 2019;119(2):203-12. Go to original source... Go to PubMed...
    39. Wang B, Zhang B, Shen Y,et al. Validation of two revised, simplified criteria for assessing sepsis-associated disseminated intravascular coagulation in ICU patients with sepsis-3: a retrospective study. Lab Med. 2022; 54(3):291-298. Go to original source... Go to PubMed...
    40. Lu Z, Zhang J, Hong J, Wu J, et al. Development of a nomogram to predict 28-day mortality of patients with sepsis-induced coagulopathy: an analysis of the MIMIC-III database. Front Med. 2021;8:661710. Go to original source... Go to PubMed...
    41. Rabinovich A, Abdul-Kadir R, Thachil J, et al. DIC in obstetrics: diagnostic score, highlights in management, and international registry-communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2019;17:1562-6. Go to original source... Go to PubMed...
    42. Adelborg K, Larsen JB, Hvas A-M. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. British Journal of Haematology. 2021;9:803-818. Go to original source... Go to PubMed...
    43. Squizzato A, Hunt BJ, Kinasewitz GT, et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost. 2016;115:896-904. Go to original source... Go to PubMed...
    44. Fu S, Yu S, Wang L, Ma X, Li X. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and metaanalysis. Anesthesiol. 2022;22(1):28. Go to original source... Go to PubMed...
    45. Omidkhoda N, Abedi F, Ghavami V, et al. The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization: a systematic review. Int J Clin Pract. 2022; 2022:2226761. Go to original source... Go to PubMed...
    46. Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecularweight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Sci Rep. 2016;6:25984. Go to original source... Go to PubMed...
    47. Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80(03):389-402. Go to original source... Go to PubMed...
    48. Warren BL, Eid A, Singer P. et al. KyberSept Trial Study Group.Caringfor the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869-1878 Go to original source... Go to PubMed...
    49. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(01):90-97. Go to original source... Go to PubMed...
    50. Tagami T. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: reevaluation of a "pendulum effect" drug using a nationwide database. J Thromb Haemost. 2018;16(3):458-61. Go to original source... Go to PubMed...
    51. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35(4):349-54. Go to original source... Go to PubMed...
    52. Vincent JL, Francois B, Zabolotskikh I, et al. SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET Randomized Clinical Trial. JAMA. 2019;321(20):1993-2002. Go to original source... Go to PubMed...
    53. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709. Go to original source... Go to PubMed...
    54. Nadel S, Goldstein B, Williams MD, et al. REsearching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective (RESOLVE) Study Group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369(9564):836-843. Go to original source... Go to PubMed...
    55. Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (address) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and low risk of death. N Engl J Med. 2005;353(13):1332-1341. Go to original source... Go to PubMed...
    56. Ranieri VM, Thompson BT, Barie PS, et al. PROWESS-SHOCK Study Group. Drotrecoginalfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055-2064. Go to original source... Go to PubMed...
    57. Abraham E, Reinhart K, Opal S, et al. OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238-247. Go to original source... Go to PubMed...
    58. Wunderink RG, Laterre PF, Francois B, et al. CAPTIVATE Trial Group. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. AmJ Respir Crit Care Med. 2011;183(11):1561-1568 Go to original source... Go to PubMed...
    59. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131:845-54. Go to original source... Go to PubMed...
    60. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2:15. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.